Article
Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC.
The New England journal of medicine - 23 Nov 2023
Planchard David, Jänne Pasi A, Cheng Ying, Yang James C-H, Yanagitani Noriko, Kim Sang-We, Sugawara Shunichi, Yu Yan, Fan Yun, Geater Sarayut L, Laktionov Konstantin, Lee Chee K, Valdiviezo Natalia, Ahmed Samreen, Maurel Jean-Marc, Andrasina Igor, Goldman Jonathan, Ghiorghiu Dana, Rukazenkov Yuri, Todd Alex, Kobayashi Kunihiko
Abstract excerpt
BACKGROUND: Osimertinib is a third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) that is selective for EGFR-TKI-sensitizing and EGFR T790M resistance mutations. Evidence suggests that the addition of chemotherapy may extend the benefits of EGFR-TKI therapy. METHODS: In this phase 3, international, open-label trial, we randomly assigned in a 1:1 ratio patients with EGFR-mutated...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.